通过通过自我调节的多功能纳米调节器对抗阿尔茨海默病,使神经血管单元正常化
Xue Xia1, Ya Wei1, Qianqian Huang1
1Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, West China School of Pharmacy, Mental Health Center and National Chengdu Center for Safety Evaluation of Drugs, West China Hospital, Sichuan University, Chengdu 610041, China.
Acta pharmaceutica Sinica. B
|January 14, 2025
概括
研究人员开发了一种智能纳米药物 (siR/PIO@RP),通过向神经血管单元 (NVU) 来治疗阿尔茨海默病 (AD). 这种纳米药物自我调节其释放以减少Aβ斑块和神经炎症,提供了一个新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 生物技术是生物技术.
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经血管单元 (NVU) 对大脑平衡至关重要.
- NVU功能障碍是阿尔茨海默病 (AD) 病理学的关键因素.
- 准NVU功能障碍为AD提供了潜在的治疗途径.
研究的目的:
- 开发一种自我调节的多功能纳米调节器 (siR/PIO@RP) 用于协同AD治疗.
- 调查siR/PIO@RP能够准受损的血脑屏障并释放治疗剂的能力.
- 根据RAGE表达水平评估siR/PIO@RP的自我调节机制.
主要方法:
- 制造一个自我调节的多功能纳米调节器 (siR/PIO@RP).
- 评估 siR/PIO@RP 导航到受损的血脑屏障的能力.
- 评估siR/PIO@RP的治疗效果,包括Aβ负载减轻,神经炎症缓解和NVU功能恢复.
主要成果:
- siR/PIO@RP纳米调节器展示了智能导航到受损的血脑屏障部位.
- siR/PIO@RP通过基于RAGE表达的反循环表现出分布的自我调节.
- 纳米调节器有效地降低了大脑Aβ负载,缓解了神经炎症,并改善了NVU功能障碍.
结论:
- 正常化NVU功能障碍是缓解AD症状的一个有希望的策略.
- 开发的siR/PIO@RP纳米调节器为AD治疗提供了一种多功能和自我调节的方法.
- 这项研究为治疗AD等神经退行性疾病的先进纳米医学提供了概念证明.
相关概念视频
Alzheimer's Disease: Treatment
161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
Alzheimer's Disease: Overview
440
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
440
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
The Blood-brain Barrier
46.7K
Overview
46.7K


